Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 21st World Congress on Gastrointestinal Cancer /
CAPTEM vs FOLFIRI as second-line treatment for mCRC patients

3rd - 7th Jul 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.07.19
Views: 323
Rating:

Dr Filippo Pietrantonio - ‎IRCCS Istituto Nazionale dei Tumori Foundation, Milan, Italy

Dr Filippo Pietrantonio speaks to ecancer at ESMO 21st World Congress on Gastrointestinal Cancer about a phase II trial comparing CAPTEM versus FOLFIRI as a second-line treatment for MGMT-methylated, RAS-mutated metastatic colorectal cancer patients.

The aim of the study was to demonstrate a superiority of CAMPTEM in terms of progression-free survival (PFS) over FOLFIRI. Dr Pietrantonio reports that the primary endpoint was not met, however CAPTEM was shown to have similar PFS, overall survival, overall response rate and disease control rate (DCR) with a more favourable toxicity profile, compliance and quality of life.

Dr Pietrantonio explains that the next steps would be phase III studies ideally restricted to MGMT-negative population, due to patients with MGMT immunohistochemistry receiving CAPTEM achieving a significantly worse outcome in terms of both PFS and DCR.

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation